Article

Future directions in development of VEGF antagonists

Ranibizumab (Lucentis, Genentech) has revolutionized the treatment of age-related macular degeneration, but the impressive results from clinical trials lead to new questions. Is long-term suppression of vascular endothelial growth factor (VEGF) in the eye safe? Do other members of the VEGF gene family contribute to retinal vascular diseases? Are other cytokines or growth factors involved in disease pathogenesis? Are there safe and effective delivery methods other than monthly injections?

Ranibizumab (Lucentis, Genentech) has revolutionized the treatment of age-related macular degeneration, but the impressive results from clinical trials lead to new questions. Is long-term suppression of vascular endothelial growth factor (VEGF) in the eye safe? Do other members of the VEGF gene family contribute to retinal vascular diseases? Are other cytokines or growth factors involved in disease pathogenesis? Are there safe and effective delivery methods other than monthly injections?

Peter A. Campochiaro, MD, professor of ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital School of Medicine, Baltimore, addressed these issues in a symposium on the use of VEGF inhibitors. He noted that results of a study in a transgenic mouse model in which VEGF signaling was blocked found that there was no effect on the vasculature or ERG function and no decrease in retinal ganglion cells or axons in the optic nerve over a 7-month period.

"Therefore, it appears that blockage of VEGF-A for long periods of time is safe," Dr. Campochiaro said.

He also described a study suggesting that other VEGF family members besides VEGF-A play a role in retinal disease. Preclinical and clinical studies of a chimeric protein that binds VEGF-A and B and placental growth factor (VEGF Trap-Eye, Regeneron) show that it causes a substantial reduction in choroidal neovascularization (CNV).

Platelet-derived growth factor-B (PDGF-B) also is likely to be involved in development of retinal disease. According to Dr. Campochiaro, kinase inhibitors that block both VEGF and PDGF were highly effective in preclinical studies, using a synergistic effect to completely eliminate CNV. A prodrug for a kinase inhibitor was tested in a small clinical trial; it was administered topically b.i.d. for 30 days and substantially reduced thickening and subretinal fluid. It was a pigmented agent that produced colored deposits on the cornea in many patients, however, and the trial was stopped.

"It does provide proof of concept for topical delivery of kinase inhibitors," Dr. Campochiaro said.

"VEGF antagonists provide a benefit for [CNV] and other disease indications as well, such as retinal neovascularization and ischemia due to macular edema," he continued. "They're certainly here to stay and will be the baseline on which other things are added. Improvements are likely, and certainly it's very likely that the newer antagonists will have greater potency and less specificity. In addition, there will be new modes of delivery, including topical delivery and sustained delivery."

Dr. Campochiaro said that sustained delivery of proteins is difficult, but possible, and that studies of this technology are underway. Sustained delivery of small kinase inhibitors is very feasible and is likely to be achieved in the near future.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.